Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patriarca, F
Right arrow Articles by Fanin, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patriarca, F
Right arrow Articles by Fanin, R
Haematologica, Vol 89, Issue 11, 1352-1359
Copyright © 2004 by Ferrata Storti Foundation

Journal Article

Infliximab treatment for steroid-refractory acute graft-versus-host disease

F Patriarca, A Sperotto, D Damiani, G Morreale, F Bonifazi, A Olivieri, F Ciceri, G Milone, S Cesaro, G Bandini, G Dini, P Corradini, and R Fanin

Division of Haematology, Dept. of Clinical and Morphological Research, University of Udine, Italy. francesca.patriarca@med.uniud.it

BACKGROUND AND OBJECTIVES: Tumor necrosis factor a is one of the principal cytokines involved in the pathogenesis of acute graft-versus-host-disease (GVHD). Infliximab is an antibody to this cytokine. DESIGN AND METHODS: We performed a retrospective analysis to evaluate the activity of infliximab in 32 patients with severe steroid-refractory acute GVHD. The patients received a median of 3 weekly courses of infliximab. The main organs involved in the patients were skin (n=2) liver (n=1), bowel (n=19), liver and bowel at the same stage (n=10). RESULTS: Nineteen out 32 patients (59%) responded to infliximab with 6 (19%) complete and 13 (40%) partial responses. Age younger than 35 years, intestinal involvement and a longer time between hematopoietic stem cell transplantation and infliximab administration were factors predicting a favorable response. Infective episodes developed in 23/32 (72%) patients. All the 13 unresponsive patients died of GVHD shortly after infliximab. Thirteen of 19 responsive patients were alive at a median follow-up of 449 days (range 155-842) after infliximab, with no signs of chronic GVHD (n=5), limited (n=5) or extensive involvement (n=3). Six patients who responded subsequently died, one of chronic lung GVHD, the others of vascular complications or infections (2 fungal diseases). INTERPRETATION AND CONCLUSIONS: We conclude that infliximab is active in the treatment of severe steroid-refractory acute GVHD, particularly when the intestine is involved. Infections commonly followed its administration. The clinical activity of infliximab and the possibility that it increases the risk of infections are worth investigating in prospective trials.


This article has been cited by other articles:


Home page
 BloodHome page
J. E. Levine, S. Paczesny, S. Mineishi, T. Braun, S. W. Choi, R. J. Hutchinson, D. Jones, Y. Khaled, C. L. Kitko, D. Bickley, et al.
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
Blood, February 15, 2008; 111(4): 2470 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. S Kim
Treatment Options in Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation
Ann. Pharmacother., September 1, 2007; 41(9): 1436 - 1444.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
M. G. Lebwohl
Advances in Psoriasis
Arch Dermatol, December 1, 2005; 141(12): 1589 - 1590.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.